460 related articles for article (PubMed ID: 32780949)
1. What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study.
Rush AJ; South C; Jha MK; Jain SB; Trivedi MH
J Clin Psychiatry; 2020 Aug; 81(5):. PubMed ID: 32780949
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection.
Jha MK; Minhajuddin A; Gadad BS; Greer TL; Mayes TL; Trivedi MH
Brain Behav Immun; 2017 Nov; 66():103-110. PubMed ID: 28698115
[TBL] [Abstract][Full Text] [Related]
3. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Brent D; Emslie G; Clarke G; Wagner KD; Asarnow JR; Keller M; Vitiello B; Ritz L; Iyengar S; Abebe K; Birmaher B; Ryan N; Kennard B; Hughes C; DeBar L; McCracken J; Strober M; Suddath R; Spirito A; Leonard H; Melhem N; Porta G; Onorato M; Zelazny J
JAMA; 2008 Feb; 299(8):901-913. PubMed ID: 18314433
[TBL] [Abstract][Full Text] [Related]
4. PSYCHOTHERAPY VERSUS PHARMACOTHERAPY FOR POSTTRAUMATIC STRESS DISORDER: SYSTEMIC REVIEW AND META-ANALYSES TO DETERMINE FIRST-LINE TREATMENTS.
Lee DJ; Schnitzlein CW; Wolf JP; Vythilingam M; Rasmusson AM; Hoge CW
Depress Anxiety; 2016 Sep; 33(9):792-806. PubMed ID: 27126398
[TBL] [Abstract][Full Text] [Related]
5. Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.
Jha MK; Wakhlu S; Dronamraju N; Minhajuddin A; Greer TL; Trivedi MH
J Affect Disord; 2018 Jul; 234():34-37. PubMed ID: 29522941
[TBL] [Abstract][Full Text] [Related]
6. Prognostic subgroups for citalopram response in the STAR*D trial.
Jakubovski E; Bloch MH
J Clin Psychiatry; 2014 Jul; 75(7):738-47. PubMed ID: 24912106
[TBL] [Abstract][Full Text] [Related]
7. Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial.
Kato T; Furukawa TA; Mantani A; Kurata K; Kubouchi H; Hirota S; Sato H; Sugishita K; Chino B; Itoh K; Ikeda Y; Shinagawa Y; Kondo M; Okamoto Y; Fujita H; Suga M; Yasumoto S; Tsujino N; Inoue T; Fujise N; Akechi T; Yamada M; Shimodera S; Watanabe N; Inagaki M; Miki K; Ogawa Y; Takeshima N; Hayasaka Y; Tajika A; Shinohara K; Yonemoto N; Tanaka S; Zhou Q; Guyatt GH;
BMC Med; 2018 Jul; 16(1):103. PubMed ID: 29991347
[TBL] [Abstract][Full Text] [Related]
8. Hippocampal Subfields in Acute and Remitted Depression-an Ultra-High Field Magnetic Resonance Imaging Study.
Kraus C; Seiger R; Pfabigan DM; Sladky R; Tik M; Paul K; Woletz M; Gryglewski G; Vanicek T; Komorowski A; Kasper S; Lamm C; Windischberger C; Lanzenberger R
Int J Neuropsychopharmacol; 2019 Aug; 22(8):513-522. PubMed ID: 31175352
[TBL] [Abstract][Full Text] [Related]
9. Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
Jha MK; Minhajuddin A; Gadad BS; Greer T; Grannemann B; Soyombo A; Mayes TL; Rush AJ; Trivedi MH
Psychoneuroendocrinology; 2017 Apr; 78():105-113. PubMed ID: 28187400
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant Response Trajectories and Associated Clinical Prognostic Factors Among Older Adults.
Smagula SF; Butters MA; Anderson SJ; Lenze EJ; Dew MA; Mulsant BH; Lotrich FE; Aizenstein H; Reynolds CF
JAMA Psychiatry; 2015 Oct; 72(10):1021-8. PubMed ID: 26288246
[TBL] [Abstract][Full Text] [Related]
11. Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial.
Grieve SM; Korgaonkar MS; Etkin A; Harris A; Koslow SH; Wisniewski S; Schatzberg AF; Nemeroff CB; Gordon E; Williams LM
Trials; 2013 Jul; 14():224. PubMed ID: 23866851
[TBL] [Abstract][Full Text] [Related]
12. What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study's patient-level data with fidelity to the original research protocol.
Pigott HE; Kim T; Xu C; Kirsch I; Amsterdam J
BMJ Open; 2023 Jul; 13(7):e063095. PubMed ID: 37491091
[TBL] [Abstract][Full Text] [Related]
13. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study.
Perlis RH; Patrick A; Smoller JW; Wang PS
Neuropsychopharmacology; 2009 Sep; 34(10):2227-36. PubMed ID: 19494805
[TBL] [Abstract][Full Text] [Related]
14. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression.
Lenze EJ; Mulsant BH; Roose SP; Lavretsky H; Reynolds CF; Blumberger DM; Brown PJ; Cristancho P; Flint AJ; Gebara MA; Gettinger TR; Lenard E; Miller JP; Nicol GE; Oughli HA; Pham VT; Rollman BL; Yang L; Karp JF
N Engl J Med; 2023 Mar; 388(12):1067-1079. PubMed ID: 36867173
[TBL] [Abstract][Full Text] [Related]
15. Melancholic features and treatment outcome to selective serotonin reuptake inhibitors in major depressive disorder: A re-analysis of the STAR*D trial.
Szmulewicz A; Valerio MP; Lomastro J; Martino DJ
J Affect Disord; 2024 Feb; 347():101-107. PubMed ID: 37981037
[TBL] [Abstract][Full Text] [Related]
16. Graphical methods for understanding changes in states: Understanding medication use pathways.
Wise EA; Adams RJ; Lyketsos CG; Leoutsakos JM
Int J Methods Psychiatr Res; 2022 Dec; 31(4):e1932. PubMed ID: 35894783
[TBL] [Abstract][Full Text] [Related]
17. A genetic risk score to predict treatment nonresponse in psychotic depression.
Ter Hark SE; Coenen MJH; Vos CF; Aarnoutse RE; Nolen WA; Birkenhager TK; van den Broek WW; Schellekens AFA; Verkes RJ; Janzing JGE
Transl Psychiatry; 2024 Mar; 14(1):132. PubMed ID: 38431658
[TBL] [Abstract][Full Text] [Related]
18. Machine Learning Prediction of Quality of Life Improvement During Antidepressant Treatment of Patients With Major Depressive Disorder: A STAR*D and CAN-BIND-1 Report.
Phaterpekar T; Nunez JJ; Morton E; Liu YS; Cao B; Frey BN; Milev RV; Müller DJ; Rotzinger S; Soares CN; Taylor VH; Uher R; Kennedy SH; Lam RW
J Clin Psychiatry; 2023 Nov; 85(1):. PubMed ID: 37967350
[No Abstract] [Full Text] [Related]
19. Potential efficacy of dopaminergic antidepressants in treatment resistant anergic-anhedonic depression results of the chronic anergic-anhedonic depression open trial - CADOT.
Dormegny-Jeanjean LC; de Billy C; Mainberger O; Weibel S; Schorr B; Obrecht A; Landré L; Berna F; Causin JB; Blanc F; Danila V; Tomsa M; Pfleger G; Meyer C; Humbert I; Javelot H; Meyer G; Bertschy G; Foucher JR
Front Psychiatry; 2023; 14():1194090. PubMed ID: 37829759
[TBL] [Abstract][Full Text] [Related]
20. Cumulative remission rate after sequential treatments in depression: reappraisal of the STAR*D trial data.
Sakurai H; Noma H; Watanabe K; Uchida H; Furukawa TA
World Psychiatry; 2024 Feb; 23(1):156-157. PubMed ID: 38214644
[No Abstract] [Full Text] [Related]
[Next] [New Search]
